Clinical Trial Update: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF [Phase 3]

View source ↗

Summary

Phase 3 trial of levosimendan to improve exercise limitation in patients with pulmonary hypertension due to heart failure with preserved ejection fraction (PH-H…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure with Preserved Ejection Fraction
• Pulmonary Hypertension

Drugs mentioned

• Levosimendan (levosimendan)

Snippet

Sponsor: Tenax Therapeutics, Inc. | Conditions: Pulmonary Hypertension | Phase 3 | Status: RECRUITING